Regulation Of Stem cell Medicine–What Is the Future with the FDA
Posted May 14 2011 2:40am
Since stem cell research and development is moving so fast, this article brings up a lot of good questions as to how regulation will or will not take place. As the rules/laws read, culturing stem cells in the eye of the FDA is considered a “drug”. The article talks about a “tool kit” being in place in a few years at a physician’s office. Guidelines are being developed by the American Stem Cell Therapy Association for safe use, like fertility clinics where state laws would have jurisdiction.
Stem cells are taken from the patient and injected back, no cells from outside sources and this kind of reminds me a bit of the Provenge cycle with the anti immune drug with being processed and re-injected so in time we will have entirely new classes of drugs and treatments for a lot less cost potentially. One remark made here too is the fact that a $60 billion dollar drug and device care system would be in time reduced to a $6 Billion dollar stem cell business and of course there’s not much more that needs to be said there with the number of drug and device companies in business, although not all would go away but the number of devices and drugs that we used today could shrink. BD
Within the next five years, it’s quite possible that will come into routine possession of a remarkable set of tools — a brand new way of dealing with the frailty and disabilities of aging. The tool kit is derived from the themselves, amplified in culture, and infused back into the patient according to a precise protocol. It would be such a leap from today’s diagnostics and treatments; it could only be called revolutionary.
The purpose of employing is to prevent rejection of histo-incompatible by the patient’s . But it’s also possible that these new therapies could slip from our grasp, at least in the US. If we’re not careful, these therapies could become the exclusive domain of the pharmaceutical industry, as regulated by the Federal and Administration (FDA). This could push the availability of this tool kit 15 to 20 years into the future. The opportunity-cost in terms of morbidity and mortality could be catastrophic.
We’ve got an organization to formulate guidelines, and we’ve got clinicians working to form a . But the FDA doesn’t appreciate that. We only do adult from the same person. But the FDA contends that if one cultures at all, regardless of the use of those , then it’s a prescription .” He points out that the age-management community has seen many instances where the FDA has tried to insert itself into the practice of — although this has been strictly prohibited by Congress — and this is just the latest. “Compounding pharmacies coming under FDA pressure for a long time, and have now organized and set up their own standards and guidelines as a way to combat that interference.”
“You’re talking about replacing $60 billion in - and device-care with $6 billion in stem- care,” Dr. Centeno observes.